The initiation of the ACC Ambulatory Surgical Center Registry comes at a time when hospitals are expanding their structural heart programs. The registry is providing valuable details about which patients should stay at the hospital and which can be treated in an outpatient setting.

The balloon-free catheter, which already had a successful launch in the United States, has been associated with positive outcomes and the ability to reach certain lesions more accurately than balloon-based IVL platforms.

The Symphony Thrombectomy System eliminates tradeoffs between two priorities—leveraging large-bore power and ease of use vs. efficiently reducing clot burden and delivering improved speed. 

The technologies and tools of the cardiac catheterization lab have evolved in recent years, allowing interventionalists to perform procedures with more precision than ever. Angiographic imaging, meanwhile, has remained relatively consistent—but that is all starting to change.

The company describes Vivid Pioneer as its “most advanced, ultra-premium and adaptive cardiovascular ultrasound system yet.” It includes new and improved AI capabilities and a compact design that is still fully functional in tight workspaces. 

“It is your responsibility to be the patient’s advocate,” one expert explained. “We, as the nurses and technologists, have to speak up when we see something that isn’t right.”

Customers with these devices on hand are asked to return them right away. No serious injuries have been reported at this time, but the presence of residual particulates can lead to such side effects as pulmonary embolism and deep vein thrombosis.

Study shows same-day discharge is feasible for carefully selected, uncomplicated ACS patients.